CN101355935A - 用于治疗糖尿病的三嗪衍生物与hmg-coa还原酶抑制剂的组合 - Google Patents
用于治疗糖尿病的三嗪衍生物与hmg-coa还原酶抑制剂的组合 Download PDFInfo
- Publication number
- CN101355935A CN101355935A CNA2006800508489A CN200680050848A CN101355935A CN 101355935 A CN101355935 A CN 101355935A CN A2006800508489 A CNA2006800508489 A CN A2006800508489A CN 200680050848 A CN200680050848 A CN 200680050848A CN 101355935 A CN101355935 A CN 101355935A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- alkoxyl
- amino
- optional
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
Claims (31)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0600343A FR2896158B1 (fr) | 2006-01-13 | 2006-01-13 | Combinaison de derives de triazine et d'inhibiteurs de la hmg-coa reductase. |
FR06/00343 | 2006-01-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101355935A true CN101355935A (zh) | 2009-01-28 |
Family
ID=36649749
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2006800508489A Pending CN101355935A (zh) | 2006-01-13 | 2006-12-18 | 用于治疗糖尿病的三嗪衍生物与hmg-coa还原酶抑制剂的组合 |
Country Status (14)
Country | Link |
---|---|
US (1) | US20100158999A1 (zh) |
EP (1) | EP1978951A2 (zh) |
JP (1) | JP2009523141A (zh) |
KR (1) | KR20080085208A (zh) |
CN (1) | CN101355935A (zh) |
AR (1) | AR059031A1 (zh) |
AU (1) | AU2006334733A1 (zh) |
BR (1) | BRPI0621420A2 (zh) |
CA (1) | CA2636840A1 (zh) |
EA (1) | EA200801666A1 (zh) |
FR (1) | FR2896158B1 (zh) |
IL (1) | IL192594A0 (zh) |
WO (1) | WO2007079916A2 (zh) |
ZA (1) | ZA200806937B (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6949245B1 (en) * | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
EP2197858B1 (en) * | 2007-08-31 | 2014-07-02 | HanAll Biopharma Co., Ltd. | 1,3,5-triazine-2,4,6-triamine compound or pharmaceutical acceptable salt thereof, and pharmaceutical composition comprising the same |
AU2009326965A1 (en) * | 2008-12-12 | 2011-06-23 | Poxel | Tetrahydrotriazine compounds for treating diseases associated with AMPK activity |
FR2948028B1 (fr) * | 2009-07-17 | 2011-12-02 | Merck Sante Sas | Association d'un inhibiteur de l'echangeur sodium-proton et d'un derive amine de dihydro-1,3,5-triazine |
EP2602249B1 (en) * | 2011-12-06 | 2015-08-12 | F.I.S. Fabbrica Italiana Sintetici S.p.A. | Synthesis of rosuvastatin by means of co-crystals |
JP7266616B2 (ja) | 2018-06-14 | 2023-04-28 | ポクセル | 糖尿病の治療において使用するためのトリアジン誘導体を含むフィルムコーティング錠剤 |
JP7093473B2 (ja) * | 2019-12-13 | 2022-06-29 | 住友ファーマ株式会社 | 製造性及び溶出性に優れた小型錠剤 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3651816B2 (ja) * | 1995-07-03 | 2005-05-25 | 三共株式会社 | 動脈硬化症予防および治療剤 |
FR2804113B1 (fr) * | 2000-01-26 | 2004-06-18 | Lipha | Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique |
FR2853650B1 (fr) * | 2003-04-10 | 2006-07-07 | Merck Sante Sas | Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance |
EP1510208A1 (en) * | 2003-08-22 | 2005-03-02 | Fournier Laboratories Ireland Limited | Pharmaceutical composition comprising a combination of metformin and statin |
-
2006
- 2006-01-13 FR FR0600343A patent/FR2896158B1/fr not_active Expired - Fee Related
- 2006-12-18 EA EA200801666A patent/EA200801666A1/ru unknown
- 2006-12-18 BR BRPI0621420-7A patent/BRPI0621420A2/pt not_active IP Right Cessation
- 2006-12-18 JP JP2008549782A patent/JP2009523141A/ja active Pending
- 2006-12-18 CA CA002636840A patent/CA2636840A1/en not_active Abandoned
- 2006-12-18 KR KR1020087019392A patent/KR20080085208A/ko not_active Application Discontinuation
- 2006-12-18 US US12/160,504 patent/US20100158999A1/en not_active Abandoned
- 2006-12-18 WO PCT/EP2006/012184 patent/WO2007079916A2/en active Application Filing
- 2006-12-18 CN CNA2006800508489A patent/CN101355935A/zh active Pending
- 2006-12-18 EP EP06829705A patent/EP1978951A2/en not_active Withdrawn
- 2006-12-18 AU AU2006334733A patent/AU2006334733A1/en not_active Abandoned
-
2007
- 2007-01-12 AR ARP070100137A patent/AR059031A1/es unknown
-
2008
- 2008-07-02 IL IL192594A patent/IL192594A0/en unknown
- 2008-08-12 ZA ZA200806937A patent/ZA200806937B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
WO2007079916A3 (en) | 2007-12-06 |
FR2896158B1 (fr) | 2008-09-12 |
IL192594A0 (en) | 2009-09-22 |
AR059031A1 (es) | 2008-03-12 |
ZA200806937B (en) | 2009-07-29 |
US20100158999A1 (en) | 2010-06-24 |
EA200801666A1 (ru) | 2008-12-30 |
FR2896158A1 (fr) | 2007-07-20 |
KR20080085208A (ko) | 2008-09-23 |
AU2006334733A1 (en) | 2007-07-19 |
EP1978951A2 (en) | 2008-10-15 |
WO2007079916A2 (en) | 2007-07-19 |
BRPI0621420A2 (pt) | 2011-12-06 |
CA2636840A1 (en) | 2007-07-19 |
JP2009523141A (ja) | 2009-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101355933A (zh) | 三嗪衍生物与胰岛素增敏剂的组合 | |
CN101355935A (zh) | 用于治疗糖尿病的三嗪衍生物与hmg-coa还原酶抑制剂的组合 | |
CN101355949A (zh) | 三嗪衍生物与胰岛素分泌促进剂的组合 | |
WO2004022538A1 (ja) | 経口用固形医薬用結晶およびそれを含む排尿障害治療用経口用固形医薬 | |
CN110944638A (zh) | 尼拉帕尼组合物 | |
KR20080043852A (ko) | 신규 투여 제형 | |
WO2006025378A1 (ja) | 高脂血症治療剤 | |
CN1838949A (zh) | 包含二甲双胍和他汀的组合的药物组合物 | |
JP6621534B2 (ja) | 慢性咳の処置のためのオルブピタント | |
BRPI0712360A2 (pt) | método para intensificação de função cognitiva | |
CN102647986A (zh) | 治疗增殖性障碍和其它由bcr-abl、c-kit、ddr1、ddr2或pdgf-r激酶活性介导的病理学病症的方法 | |
JP2018507874A (ja) | 過剰な体脂肪の治療処置または美容処置のためのnk−3受容体拮抗薬 | |
JP2022504943A (ja) | アミノピリミジン誘導体又はその塩を含む経口投与用医薬組成物 | |
MX2007001655A (es) | Composicion y metodo para la biodisponibilidad mejorada y la administracion al cerebro mejorada de acido 5, 5-difenil barbiturico. | |
US20200157042A1 (en) | Type-g crystal form of fenolamine, preparation method, composition and use thereof | |
MX2013002955A (es) | Compuesto y composición farmaceutica, uso de un compuesto y método para el tratamiento de los trastornos asociados a los receptores serotoninérgicos 5-ht1a y 5-ht2a. | |
US6593331B2 (en) | Method for treatment of pain | |
CN101355932A (zh) | 三嗪衍生物与PPARα激动剂的组合 | |
MX2008008887A (en) | Combination of triazine derivatives and hmg- coa reductase inhibitors for the treatment of diabetes | |
JP6643330B2 (ja) | アルツハイマー病の処置用のn−[2−(6−フルオロ−1h−インドール−3−イル)エチル]−3−(2,2,3,3−テトラフルオロプロポキシ)ベンジルアミン塩酸塩の新規な多形形態 | |
CN108358811B (zh) | 苯乙酮类化合物、其制备方法及其在调血脂方面的应用 | |
CN115887462A (zh) | 一种口服药物组合物 | |
SG185445A1 (en) | Association of xanthine oxidase inhibitors and statins and use thereof | |
ZA200503520B (en) | Use of 5-HT2 receptor antagonists for the treatment of sleep disorders. | |
MX2008008895A (en) | Combination of triazine derivatives and insulin sensitisers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1128231 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: BOCSILE CO.,LTD. Free format text: FORMER OWNER: MERCK PATENT GMBH Effective date: 20091106 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20091106 Address after: lyon Applicant after: Polk Zale Corporation Address before: Darmstadt Applicant before: Merck Patent GmbH |
|
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20090128 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1128231 Country of ref document: HK |